Affective neural circuits and inflammatory markers linked to depression and anxiety symptoms in patients with comorbid obesity.

Autor: Hallihan H; Department of Medicine, University of Illinois at Chicago, Chicago, IL, 60608, USA., Tsai P; Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA., Lv N; Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL, 60608, USA., Xiao L; Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, USA., Peñalver Bernabé B; Department of Biomedical Engineering, College of Medicine, Chicago, IL, 60607, USA., Wu Y; Department of Mathematics, Statistics, and Computer Science, College of Liberal Arts and Sciences, Chicago, IL, 60607, USA., Pandey GN; Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA., Williams LM; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA., Ajilore OA; Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA., Ma J; Department of Medicine, University of Illinois at Chicago, Chicago, IL, 60608, USA. Electronic address: maj2015@uic.edu.
Jazyk: angličtina
Zdroj: Journal of psychiatric research [J Psychiatr Res] 2023 Apr; Vol. 160, pp. 9-18. Date of Electronic Publication: 2023 Feb 03.
DOI: 10.1016/j.jpsychires.2023.01.044
Abstrakt: Although we have effective treatments for depression and anxiety, we lack mechanistic understanding or evidence-based strategies to tailor these treatments in the context of major comorbidities such as obesity. The current feasibility study uses functional neuroimaging and biospecimen data to determine if changes in inflammatory markers, fecal short-chain fatty acids, and neural circuit-based targets can predict depression and anxiety outcomes among participants with comorbid obesity. Blood and stool samples and functional magnetic resonance imaging data were obtained at baseline and 2 months, during the parent ENGAGE-2 trial. From 30 participants with both biospecimen and fMRI data, this subsample study explored the relationship among changes in inflammatory markers and fecal short-chain fatty acids and changes in neural targets, and their joint relationship with depression and anxiety symptoms. Bivariate and partial correlation, canonical correlation, and partial least squares analyses were conducted, with adjustments for age, sex, and treatment group. Initial correlation analyses revealed three inflammatory markers (IL-1RA, IL-6, and TNF-α) and five neural targets (in Negative Affect, Positive Affect, and Default Mode Circuits) with significantly associated changes at 2 months. Partial least squares analyses then showed that changes in IL-1RA and TNF-α and changes in three neural targets (in Negative Affect and Positive Affect Circuits) at 2 months were associated with changes in depression and anxiety symptoms at 6 months. This study sheds light on the plausibility of incorporation of inflammatory and gastrointestinal biomarkers with neural targets as predictors of depression and comorbid anxiety outcomes among patients with obesity.
Competing Interests: Declaration of competing interest JM is a paid scientific consultant for Health Mentor, Inc. (San Jose, CA). LMW is on the Scientific Advisory Board for One Mind Psyberguide and the External Advisory Board for the Laureate Institute for Brain Research. OAA is the co-founder of Keywise AI and serves on the advisory boards of Blueprint Health and Embodied Labs. The other authors report no conflicts of interest.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: